These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

This new genomic test is designed for patients diagnosed with early-stage HER2+ breast cancer, which accounts for about 20% of all breast cancer diagnoses. (Oncotype DX tests, which have been around for years, target the 80% with HER2- breast cancer.) HER2DX analyzes 27 genes and clinical features to predict the effectiveness of treatment options and the risk of recurrence. The test supports better outcomes for early-stage patients, but it could also lead to more personalized approaches for late-stage breast cancers. “This is the first genomic test to measure the immune system,” says Aleix Prat, chief scientific officer of Barcelona-based Reveal Genomics. “This opens new opportunities.” For now, the test is available worldwide, but must be processed in a Spanish lab.

More Must-Reads From TIME

Contact us at

Augmented Job Training
Next-Level EV
Flash-Frozen Coffee to Go
Athletic Apparel for the Smartwatch Era
Meditate in the Metaverse